Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of mRNA-1273.815 in Previously Vaccinated Adults
NCT06354998Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of mRNA-1273.815 in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Apr 2024; status: completed.
02
Drugs
mRNA-1273.815
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06354998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354998.